MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sulindac sodium

CAS No. : 63804-15-9

MCE 站：Sulindac sodium

产品活性：Sulindac 是 FDA 批准的非甾体抗炎剂，具有口服活性。Sulindac 作为一种免疫调节剂，可通过阻断 NF-κB 信号通路下调 PD-L1，调节 pMMR CRC 对抗 PD-L1 免疫治疗的应答，抑制结直肠癌 CRC 的发生发展。 Sulindac 还可通过下调 SIRT1 抑制 TGF-β1-诱导的 EMT，抑制肺癌细胞的迁移和侵袭。

研究领域：NF-κB  |  Immunology/Inflammation  |  Cell Cycle/DNA Damage  |  Epigenetics

作用靶点：NF-κB  |  PD-1/PD-L1  |  Sirtuin

In Vitro: Sulindac (sodium) (MK-231 (sodium)) is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, ａnd downregulation of mesenchymal markers ａnd transcription factors.
Sulindac (sodium) (MK-231 (sodium)) can inhibit TGF-β1-enhanced migration ａnd invasion of A549 cells.
SIRT1 downregulation enhances the reversal of TGF-β1-induced EMT by sulindac (sodium) ａnd SIRT1 upregulation promoted TGF-β1-induced EMT.

In Vivo: Sulindac (sodium) (MK-231 (sodium)) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) shows a significant reduction in tumor volume ａnd increases infiltration of CD8+ T lymphocytes in the tumor tissues when treated with combination therapy.
Sulindac (sodium) (MK-231 (sodium)) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P.
Sulindac (sodium) (MK-231 (sodium)) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy.
SulindacSulindac (sodium) (MK-231 (sodium)) has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose does .

相关产品：Phorbol 12-myristate 13-acetate  |  Bortezomib  |  Resveratrol  |  Nicotinamide  |  Selisistat  |  TAK-243  |  Pyrrolidinedithiocarbamate ammonium  |  JSH-23  |  Nicotinamide riboside chloride  |  3-TYP  |  Shikonin  |  Sulfasalazine  |  Dihydroartemisinin  |  Triptolide  |  Aspirin  |  Atezolizumab  |  Pembrolizumab  |  BMS-1  |  Baicalin  |  Fisetin  |  Nivolumab  |  Rocaglamide  |  BAY 11-7085  |  Betulinic acid  |  Parthenolide  |  OSS_128167  |  SN50  |  Tomivosertib  |  BMS-202  |  Suramin sodium salt

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。